Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Plays begins in Ashes after rain delay, Smith still absent

Aug 19, 2019

LONDON — Play has begun on Day 5 of the second Ashes test after a delay of 70 minutes because of rain — and Australia batsman Steve Smith has not taken the field. Smith briefly retired hurt Saturday after being hit on the side of the neck by a vicious delivery from England paceman Jofra Archer. He returned after 40 minutes off the field following concussion tests, adding 12 runs before getting out for 92. Smith didn't field at the start of England's second innings and he remained absent Sunday, with Marnus Labuschagne acting as the substitute fielder. England resumed...

Global stocks recover some ground at end of turbulent week

Aug 19, 2019

LONDON — Global stock markets looked set to end a turbulent week on a positive note although worries about the U.S. economy and the trade conflict between the U.S. and China still have the potential to derail Friday's recovery. Investors in stocks were spooked earlier this week by developments in the U.S. bond market, which was pricing in a likely recession next year. Add in worries over the trade conflict between Washington and Beijing, Brexit, weak economic performance in Germany and political unrest in Hong Kong and stock markets have endured one of their worst weeks this year. On Friday,...

Cathay Pacific CEO resigns after Beijing pressure

Aug 19, 2019

HONG KONG — The CEO of Cathay Pacific Airways, one of Hong Kong's most prominent companies, resigned Friday following pressure by Beijing on the carrier over participation by some of its employees in anti-government protests. Rupert Hogg became the highest-profile corporate casualty of official Chinese pressure on foreign and Hong Kong companies to support the ruling Communist Party's position against the protesters. Beijing jolted companies last week when it warned Cathay Pacific employees who "support or take part in illegal protests" would be barred from flying to or over the mainland. Cathay Pacific said a pilot who was charged with...

Can Tokyo's efficient rail system handle Olympic strain?

Aug 19, 2019

TOKYO — First, Tokyo Olympic fans will have to find scarce tickets and pay the price. Then there's the quandary of landing a hotel room with rates that are being inflated due to unprecedented demand. And the summer heat and humidity will be off-putting for some. Then there's one more hurdle: getting around, or even finding a tiny space to stand on Tokyo's famously efficient but over-stressed rail system. Japanese professor Azuma Taguchi at Chuo University has researched Tokyo's system for years and says it's already running at double its capacity and the Olympic crunch could push it to the...

1st test: England 76-2 at lunch v Australia; Roy, Root out

Aug 19, 2019

LONDON — Josh Hazlewood took two early wickets, including the key one of Joe Root, on his return to the Australia team before England fought back to reach lunch at 76-2 as the second Ashes test finally got underway Thursday. The paceman got an edge behind by Jason Roy for 0 off the third ball of his first over and then trapped Root, England's captain and best batsman, lbw for 14. Hazlewood had figures of 2-14 off 10 overs at Lord's after coming into Australia's attack to replace James Pattinson. Reeling at 26-2, England got through the rest of Day...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!